The Texas A&M University System on Tuesday announced a partnership with pharmaceutical giant GlaxoSmithKline to create a $91 million influenza vaccine-manufacturing facility in Bryan-College Station that officials said will generate billions of dollars worth of expenditures per year and will create close to 7,000 jobs.
Gov. Rick Perry headlined the event and said the TAMUS influenza vaccine-manufacturing center will facilitate a rapid national vaccine response.
MonoSol Rx, LLC ("MonoSol Rx"), the developer of PharmFilm drug delivery technology, announced today that it has entered into a partnership with BiondVax, an Israeli based pharmaceutical company, to develop an oral film formulation of BiondVax' universal flu vaccine, M-001, utilizing MonoSol Rx's PharmFilm delivery platform. There are significant advantages for this needle free delivery in vaccines, including ease of use, increased compliance and simplified distribution.
PrescribeWellness today launched its "A Million More" Flu Shot Initiative with the goal of increasing the influenza vaccination rate by one million more Americans.
"The flu is dangerous, threatens lives and costs the American economy billions of dollars each year," said Al Babbington, CEO of PrescribeWellness. "The flu is responsible for approximately 200,000 hospitalizations and 25,000 deaths in the United States each year, yet only 46 percent of the population currently gets flu shot immunizations."
GlaxoSmithKline announced today it has begun shipping the first lots of 2012-2013 FluLaval® (Influenza virus vaccine) and Fluarix (Influenza Virus Vaccine) to CDC distribution centers and U.S. healthcare providers. This follows approval of this season's GSK seasonal influenza vaccines by the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research.